

**For Immediate Release  
June 17, 2007**

**Contact: Mr. Tony Moses  
510.933.7600**

## **NeoVista, Inc. Reports Commencement of CABERNET Clinical Trial for the Treatment of Age-Related Macular Degeneration**

### **NeoVista, Inc. confirms first patient treated with novel Epi-Rad<sub>90</sub><sup>TM</sup> Ophthalmic System**

FREMONT, CA - (PRWEB) June 17, 2007 - NeoVista, Inc announced the official commencement of the CABERNET (Cnv secondary to Amd treated with **BE**ta **R**adiation **E**piretinal **T**herapy) clinical trial for the treatment of subfoveal choroidal neovascularization associated with wet age-related macular degeneration (AMD). Neovascular AMD is the leading cause of irreparable blindness in the elderly population, afflicting over 200,000 individuals each year in the U.S. The proprietary Epi-Rad<sub>90</sub><sup>TM</sup> Ophthalmic System, developed by NeoVista, is being utilized in the CABERNET clinical trial.

Dr. Nelson Sabates, Professor and Chairman, Department of Ophthalmology, University of Missouri-Kansas City (UMKC)/Truman Medical Centers and Director of Vision Research Center, University of Missouri-Kansas City at Truman Medical Centers treated the first patient enrolled in the CABERNET study. When asked for initial feedback on the procedure, Dr. Sabates commented, "It was no different than performing a common vitrectomy and the Epi-Rad delivery device allowed me to deliver a well focused dose of radiation to the lesion. Treating neovascular AMD using a multi-faceted approach like the use of radiation and anti-VEGF therapy may well be the next frontier in combating this sight threatening disease."

The CABERNET clinical trial will involve clinical sites in the United States, Europe, Israel, and South America. The CABERNET trial protocol is divided into two treatment arms - investigational and control.

The investigational treatment arm consists of concomitant delivery of Beta radiation, via the Epi-Rad delivery device, and an FDA approved anti-VEGF agent. The investigational treatment is administered during an outpatient surgical procedure and delivers Beta radiation directly to the area of the retina that has been compromised by the disease. An injection of the anti-VEGF agent is administered at the time of surgery with one additional injection administered 30 days after surgery. The control arm is utilizing the FDA approved anti-VEGF agent alone.

The surgery was performed in collaboration with, Saint Lukes Hospital in Kansas City. Dr. Terry J. Wall, J.D., M.D. of the Saint Lukes Cancer Institute was the attending radiation oncologist involved with the procedure.

"This is a very good day for NeoVista employees and the investors who are supporting our work," stated John N. Hendrick, President and CEO of NeoVista. "More importantly, it is a potential harbinger of hope for those suffering from wet AMD." We remain optimistic that our treatment approach will provide maximum benefit to this patient population."

**About NeoVista, Inc.**

NeoVista, Inc. is a privately held development stage medical device company based in Fremont, CA.

For more information, please visit the company website at [www.neovistainc.com](http://www.neovistainc.com)